Skip to main content

Future Goals of the Benzylisoquinolinium Ester Program

  • Conference paper
Muscle Relaxants

Abstract

This program originally sought to produce three nondepolarizing relaxants: short-, intermediate- and long-acting drugs which at the time (1975)1 were unknown. The proposed compounds are described in Fig 1. Now, twenty years later, much progress has been made, yet there is still room for additional improvement.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Savarese JJ, Kitz RJ: Does clinical anesthesia need new neuromuscular blocking agents? (Editorial). Anesthesiology 42:236–239, 1975.

    Article  PubMed  CAS  Google Scholar 

  2. Basta SJ, Savarese JJ, A1i HH, et a1: Clinical pharmacology of doxacurium chloride (BW A938U): a new long-acting nondepolarizing muscle relaxant. Anesthesiology 69: 478–485, 1988.

    Article  PubMed  CAS  Google Scholar 

  3. Belmont, MR, Lien CA, Quessy S, Abou-Donia MM, Abalos A, Eppich L, Savarese JJ: The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide-opioid-barbiturate anesthesia. Anesthesiology (May 1995) Accepted for publication.

    Google Scholar 

  4. Lien, CA, Belmont MR, Abalos A, Eppich L, Quessy S, Abou-Donia MM, Savarese JJ: The cardiovascular effects and histamine releasing properties of 51W89 in patients receiving nitrous oxide-opioid-barbiturate anesthesia. Anesthesiology (May 1995) accepted for publication.

    Google Scholar 

  5. Lien CA, Schmith VD, Belmont MR, Abalos A, Kisor DF, Savarese JJ: Pharmacokinetics of 51W89 in patients receiving nitrous oxide-opioid-barbiturate anesthesia. Anesthesiology (1995), submitted.

    Google Scholar 

  6. Savarese JJ, Ali HH, Basta SJ et al: The clinical pharmacology of mivacurium chloride (BW B10904): a short-acting nondepolarizing ester neuromuscular blocking drug. Anesthesiology 68:723–732, 1988.

    Article  PubMed  CAS  Google Scholar 

  7. Ali HH, Brull SJ, Witkowski T, Kipman A, Silverman DG, Goudsouzian NG, Bartkowski R, Weakly N: Efficacy and safety of divided-dose administration of mivacurium for rapid tracheal intubation. Anesthesiology 79:A934, 1933.

    Google Scholar 

  8. Bownes PB, Hartman GS, Chiscolm D, Savarese JJ: Antagonism of mivacurium blockade by purified human butyryl cholinesterase in cats. Anesthesiology 77:A909, 1992.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer Japan

About this paper

Cite this paper

Savarese, J.J., Lien, C.A., Belmont, M.R., Maehr, R.B., Wastila, W.B. (1995). Future Goals of the Benzylisoquinolinium Ester Program. In: Fukushima, K., Ochiai, R. (eds) Muscle Relaxants. Springer, Tokyo. https://doi.org/10.1007/978-4-431-66896-1_49

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-66896-1_49

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-66898-5

  • Online ISBN: 978-4-431-66896-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics